This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the inventions embodied in the following Patent Applications to Dimension Therapeutics, Inc. (``Dimension'') located in Cambridge, Massachusetts, USA:
Document
Prospective Grant of Exclusive Patent License: Development of Adeno-Associated Virus Vectors for the Treatment of Glycogen Storage Disease Type Ia
This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services (HHS), is contempl...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
81 FR 32761
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent License: Development of Adeno-Associated Virus Vectors for the Treatment of Glycogen Storage Disease Type Ia,” thefederalregister.org (May 24, 2016), https://thefederalregister.org/documents/2016-12169/prospective-grant-of-exclusive-patent-license-development-of-adeno-associated-virus-vectors-for-the-treatment-of-glycoge.